Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study
1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Conference reports
Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP
1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients
1 August 2011. Related: Conference reports, Antiretrovirals.
Dolutegravir: 48 week results from phase II study in treatment-naive patients
1 August 2011. Related: Conference reports, Antiretrovirals.
Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naive study
1 August 2011. Related: Conference reports, Antiretrovirals.
Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results
1 August 2011. Related: Conference reports, Antiretrovirals.
SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression
1 August 2011. Related: Conference reports, Antiretrovirals.
Hearing loss not associated with HIV in MACS and WIHS cohorts
1 August 2011. Related: Conference reports, Side effects, Coinfections and complications.
Pharmacokinetics of darunavir and fosamprenavir in pregnancy
1 August 2011. Related: Conference reports, Pregnancy, PK and drug interactions.
Low birth weight and preterm delivery
1 August 2011. Related: Conference reports, Pregnancy.
Hormonal contraception and HIV transmission risk
1 August 2011. Related: Conference reports, Pregnancy.
No difference in AIDS-free survival in children starting ART with a CD4% between 15%24% compared to deferring until less than 15% in the PREDICT trial
1 August 2011. Related: Conference reports, Paediatric care.
Paediatric antiretroviral pipeline: update on etravirine and maraviroc
1 August 2011. Related: Conference reports, Paediatric care.
Prematurity not associated with early mortality in infants on ART
1 August 2011. Related: Conference reports, Paediatric care.
More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study
1 August 2011. Related: Conference reports, Paediatric care, Side effects.
Free online resource for treatment decisions without access to genotype resistance tests
1 August 2011. Related: Conference reports, Drug resistance.
17th Annual Conference of the British HIV Association (BHIVA) 6-8 April 2011, Bournemouth
1 August 2011. Related: Conference reports.
Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors
1 August 2011. Related: Conference reports, Treatment strategies, Basic science and immunology.
18th Conference on Retroviruses and Opportunistic Infections (CROI) 27 February-3 March 2011, Boston
1 August 2011. Related: Conference reports.
Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
Lopinavir/r monotherapy used as second-line therapy in resource-limited settings
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST
1 August 2011. Related: Conference reports, Pregnancy, Paediatric care.
Lopinavir/ritonavir oral solution toxicity in neonates
1 August 2011. Related: Conference reports, Paediatric care, Side effects.
Paediatric antiretroviral pipeline: darunavir and raltegravir
1 August 2011. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART
1 August 2011. Related: Conference reports, PK and drug interactions, TB coinfection.
Initiation of ART during breastfeeding can induce multidrug resistance in infants
1 August 2011. Related: Conference reports, Pregnancy.
First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27-31 March 2011, Magaliesberg, South Africa
10 May 2011. Related: Conference reports.
17th Annual Conference of the British HIV Association (BHIVA), 6-8 April 2011, Bournemouth
1 May 2011. Related: Conference reports.
Atazanavir in pregnancy: 155 cases in London clinics
1 May 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Co-morbidity and late presentation – findings from an over 50s cohort
1 May 2011. Related: Conference reports.
Health outcomes for young adults with perinatally acquired HIV infection following transfer to adult services
1 May 2011. Related: Conference reports, Paediatric care.
The use of calcaneal stiffness index to screen for osteoporosis in HIV-infected individuals
1 May 2011. Related: Conference reports.
Frequency and characteristics of long-term non-progressors and HIV controllers in the Chelsea and Westminster cohort
1 May 2011. Related: Conference reports.
Cerebral function in perinatally HIV infected young people and HIV uninfected sibling controls
1 May 2011. Related: Conference reports.
An audit of HIV care provision for Immigration Removal Centre patients
1 May 2011. Related: Conference reports, Treatment access.
12th International Workshop on Clinical Pharmacology of HIV Therapy, 13-15 April 2011, Miami
1 May 2011. Related: Conference reports.
Quad reduces levels of oral contraceptives
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Elvitegravir/cobicistat and acid reducing agents
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Lopinavir/r reduces levels of rifabutin
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Cobicistat has little impact on CYP2D6 and CYP2B6
1 May 2011. Related: Conference reports, Antiretrovirals.
Atazanavir levels indicate need for higher dose during pregnancy
1 May 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily
1 May 2011. Related: Conference reports, Antiretrovirals.
Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir
1 May 2011. Related: Conference reports, Antiretrovirals.
Lopinavir troughs lower in children on once-daily dose with efavirenz
1 May 2011. Related: Conference reports, Antiretrovirals, Paediatric care.
Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily
1 May 2011. Related: Conference reports, Antiretrovirals, Treatment strategies.
46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany
1 May 2011. Related: Conference reports.
Rapid report: state of HCV policy, treatment, access
1 May 2011. Related: Conference reports, Antiretrovirals.
18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-3 March 2011, Boston
1 May 2011. Related: Conference reports.
When to start ART in patients co-infected with TB: results from two trials presented at CROI
1 May 2011. Related: Conference reports, Antiretrovirals, TB coinfection.
Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART
1 May 2011. Related: Conference reports, Antiretrovirals.
18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-3 March 2011, Boston
1 April 2011. Related: Conference reports.
New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340)
1 April 2011. Related: Conference reports, Antiretrovirals.
Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study
1 April 2011. Related: Conference reports, Antiretrovirals.
Antiretroviral prevention: oral PrEP, gels and treatment studies
1 April 2011. Related: Conference reports, Antiretrovirals.
Further efficacy analyses from the iPrEx study
1 April 2011. Related: Conference reports, Antiretrovirals.
Topical gels as PEP and PrEP: animal and human studies
1 April 2011. Related: Conference reports, Antiretrovirals.
Maternal risk following short course HAART
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Pre-term delivery and HAART
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
HAART more effective than AZT monotherapy in the Botswana PMTCT programme
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Lopinavir/r monotherapy for PMTCT
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
No evidence of increased risk of MTCT with sequential pregnancies in UK and Ireland
1 April 2011. Related: Conference reports, Pregnancy.
Recently infected women at the time of delivery have a higher rate of in-utero transmission in PEPI-Malawi
1 April 2011. Related: Conference reports, Pregnancy.
Reduced CCL22 concentrations in cervicovaginal secretions from pregnant women
1 April 2011. Related: Conference reports, Pregnancy.
First results from telaprevir in HIV/HCV coinfection
1 April 2011. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.